Get started
Author

Lynn A. Ueno

Observed names: L. Ueno, Lynn Ueno
Observed institution: Scripps Research Institute
ORCID: 0000-0001-8993-5168
Observed ORCID: 0000-0001-8993-5168
OpenAlex ID: A5019542520
Akt‐mediated regulation of NFκB and the essentialness of NFκB for the oncogenicity of PI3K and Akt
2009 · Dong Bai, Lynn Ueno, et al. · International Journal of Cancer · 528
PDF
MicroRNA-135b Promotes Cancer Progression by Acting as a Downstream Effector of Oncogenic Pathways in Colon Cancer
2014 · Nicola Valeri, Chiara Braconi, et al. · Cancer Cell · 288
PDF
A Small Molecule RAS-Mimetic Disrupts RAS Association with Effector Proteins to Block Signaling
2016 · Sai Krishna Athuluri-Divakar, Rodrigo Vasquez-Del Carpio, et al. · Cell · 277
PDF
Inhibitor of MYC identified in a Kröhnke pyridine library
2014 · Jonathan R. Hart, Amanda L. Garner, et al. · Proceedings of the National Academy of Sciences · 149
The butterfly effect in cancer: A single base mutation can remodel the cell
2015 · Jonathan R. Hart, Yaoyang Zhang, et al. · Proceedings of the National Academy of Sciences · 74
PDF
Oncogenic activity of the regulatory subunit p85β of phosphatidylinositol 3-kinase (PI3K)
2014 · Yoshihiro Ito, Jonathan R. Hart, et al. · Proceedings of the National Academy of Sciences · 39
Synthesis and evaluation of a cyclic imine derivative conjugated to a fluorescent molecule for labeling of proteins
2008 · Hai-Ming Guo, Maki Minakawa, et al. · Bioorganic & Medicinal Chemistry Letters · 37
Phosphatidylinositol 4,5‐bisphosphate‐specific AKT1 is oncogenic
2009 · Nadine Dannemann, Jonathan Ross Hart, et al. · International Journal of Cancer · 18
PDF
Nanobodies and chemical cross-links advance the structural and functional analysis of PI3Kα
2022 · Jonathan R. Hart, Xiao Liu, et al. · Proceedings of the National Academy of Sciences · 17
Synthetic molecules for disruption of the MYC protein-protein interface
2018 · Nicholas T. Jacob, Pedro O. Miranda, et al. · Bioorganic & Medicinal Chemistry · 12
Protein expression profiles of C3H 10T1/2 murine fibroblasts and of isogenic cells transformed by the H1047R mutant of phosphoinositide 3-kinase (PI3K)
2011 · Jonathan Ross Hart, Lujian Liao, et al. · Cell Cycle · 10
PDF
Synthetic fluorescent MYC probe: Inhibitor binding site elucidation and development of a high-throughput screening assay
2021 · Ryan J. Shirey, Jonathan R. Hart, et al. · Bioorganic & Medicinal Chemistry · 7
Structural and genetic signatures of two classes of HCV E2 neutralizing face antibodies from non-human primates immunized with a recombinant E1E2
2026 · Yen T. K. Nguyen, Fang Chen, et al. · npj Vaccines · 3
PDF
Abstract 3339: The regulatory subunit of PI3K, p85β, induces cellular transformation, enhanced cell proliferation and increased PI3K signaling
2014 · Yoshihiro Ito, Jonathan R. Hart, et al. · Cancer Research · 3
Abstract B136: CAL-120, a novel dual p110β/p110δ phosphatidylinositol-3-kinase (PI3K) inhibitor, attenuates PI3K signaling and demonstrates potent in vivo antitumor activity against solid tumors
2009 · Brian Lannutti, Adam Kashishian, et al. · Molecular Cancer Therapeutics · 2
The conserved bridging domain on HCV E1E2 glycoprotein complex is targeted by neutralizing antibodies from diverse lineages
2026 · Fang Chen, Yen Thi Kim Nguyen, et al. · Cell Reports · 1
The constitutive oncogenic and signaling activities of phosphatidylinositol 3-kinase (PI3K) isoforms p110β and p110δ
2025 · Yoshihiro Ito, Petra Pavlickova, et al. · bioRxiv (Cold Spring Harbor Laboratory)
PDF
Abstract 4479: PF-04691502, a potent and selective PI3K/mTOR dual inhibitor with antitumor activity
2010 · Shubha Bagrodia, Jing Yuan, et al. · Cancer Research
Works count: 21
Citation count: 1,468
H-index: 10
I10-index: 11
Year
Topic
Type